Dyspepsia Drugs Market Outlook:
Dyspepsia Drugs Market size was valued at USD 9.19 billion in 2025 and is expected to reach USD 13.73 billion by 2035, expanding at around 4.1% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of dyspepsia drugs is evaluated at USD 9.53 billion.
The market is expanding due to the rising prevalence of gastroesophageal reflux disease. Around the world, gastroesophageal reflux sickness has become increasingly more generally known as ongoing indigestion prompting expanded interest for compelling dyspepsia therapy.
According to the report, GERD symptoms occur in about 33% of all people worldwide. The prevalence of GERD also varies between men and women, with men more likely to have complications and extraesophageal symptoms.
In addition to this, a factor that is believed to fuel the growth of the dyspepsia drugs market is the growing need for sophisticated pharmaceutical therapies. Pharmaceutical companies can anticipate a substantial increase in demand for dyspepsia drugs as the incidence of GERD continues to grow, which confirms the market's growth.
